Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Market Cap	38.63B
Revenue (ttm)	7.03B
Net Income (ttm)	431.14M
Shares Out	n/a
EPS (ttm)	0.50
PE Ratio	89.61
Forward PE	n/a
Dividend	0.62 (2.44%)
Ex-Dividend Date	Jun 7, 2024

Volume	3,278,500
Average Volume	3,826,023
Open	27.00
Previous Close	26.75
Day's Range	26.15 - 27.50
52-Week Range	22.30 - 58.80
Beta	0.92
RSI	40.21
Earnings Date	Mar 28, 2025

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 10,185
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3347

Financial Performance

In 2024, HKG:3347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY